DexCom, Inc.   Report issue

For profit Phase 1 Phase 3 Phase 4
Founded: San Diego CA United States (1999)
Status: No NME R&D (1999)

Organization Overview

First Clinical Trial
2012
NCT01680653
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

DexCom, Inc.

Active Ingredients

Drugs in Phase 4 Trials (4)

exenatide (byetta) (1 trial)

insulin glargine (toujeo) (1 trial)

insulin human (humulin) (4 trials)

sitagliptin (januvia) (1 trial)

Drugs in Phase 3 Trials (1)

verapamil (calan) (1 trial)

Drugs in Phase 1 Trials (1)

empagliflozin (jardiance) (1 trial)

Drugs in Other Trials (1)

glucagon (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 1 (Phase 3)

Diabetes Mellitus, Type 2 (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 7